Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing
Published on 09/08/2026 at 18:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock (ISIN US3755581036) is back in the spotlight after a fresh Buy rating from Bernstein with a price target of USD 160, following Q2 2026 revenue of USD 7.8 billion and a GAAP net loss of USD 10.5 billion reported for the quarter ending June 30, 2026.TipRanks The publication of this analyst call on September 7, 2026 adds a current fundamental and sentiment signal around the stock for investors.
Analyst targets highlight upside potential
According to TipRanks, Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences and set a price target of USD 160.00 in the latest note, published on September 7, 2026. This forms a fresh reference point for investors comparing the target to the current market valuation.
The same overview reports that in a note released on August 31, 2026, Mizuho Securities also reiterated a Buy rating on Gilead Sciences stock and set a higher price target of USD 170.00, underlining that two different houses currently see double-digit upside from the present share price level.TipRanks For investors, the spread between USD 160 and USD 170 now defines a band of bullish expectations.
Q2 2026 results show growth but a sharp swing to loss
Based on Gilead Sciences' latest earnings release for the quarter ending June 30, 2026, revenue came in at USD 7.8 billion in Q2 2026, compared with USD 7.08 billion in the same quarter a year earlier, an increase of about 10.2 percent year on year.TipRanks This growth signal confirms that the core business continues to expand in the current reporting period.
However, the same source reports that Gilead Sciences posted a GAAP net loss of USD 10.5 billion in Q2 2026, versus a net profit of USD 1.96 billion in the prior-year quarter, marking a dramatic swing of around USD 12.5 billion into the red.TipRanks For investors, the contrast between double-digit revenue growth and a heavy GAAP loss is a key risk factor to monitor when interpreting the latest analyst optimism.
The Q2 2026 figures are the most recent reported quarterly numbers within the freshness window up to September 8, 2026 and therefore form the current fundamental baseline: they show that Gilead Sciences is generating high single-digit billion revenue per quarter while dealing with extraordinary charges or expenses that turned the bottom line negative.
Market valuation and peer context in biotechnology
An AI-driven sector overview lists Gilead Sciences, Inc. with a market capitalization of USD 187.39 billion as of the updated data on September 8, 2026, placing the company among the larger global biotechnology players.Aistockfinder This valuation level offers investors a sense of scale when comparing Gilead with peers such as Amgen or Biogen in the same life sciences segment.
In the same peer table, Gilead Sciences sits alongside other major names such as Amgen Inc, which is shown with a market capitalization of USD 236.37 billion, and Biogen Inc, listed at USD 32.51 billion, illustrating that Gilead is positioned closer to the upper end of the large-cap biotech range.Aistockfinder For investors, this comparison underscores that Gilead has the balance sheet and pipeline breadth typical of a sector heavyweight, even as it works through the impact of the latest GAAP loss.
Representative product focus: antiviral portfolio
Gilead Sciences is best known for its antiviral medicines, including the HIV therapy portfolio and treatments for viral hepatitis, which historically have contributed significant portions of the company’s multi-billion dollar quarterly revenue. While the Q2 2026 overview does not break out product-level sales, the USD 7.8 billion revenue figure for the quarter ending June 30, 2026 shows that the aggregate of these franchises and newer therapies continues to deliver substantial cash inflows.TipRanks For investors following the stock, the performance and competitive position of these antiviral products remain central to the long-term investment case.
Stock price level and investor view
Sector valuation data indicate that, at a market capitalization of about USD 187.39 billion as of September 8, 2026, Gilead Sciences stock trades in a range that leaves room relative to the USD 160 and USD 170 analyst price targets from Bernstein and Mizuho.TipRanksAistockfinder The combination of roughly 10.2 percent year-on-year revenue growth in Q2 2026 and the sharp swing from a USD 1.96 billion net profit to a USD 10.5 billion GAAP net loss means that, for investors, the next earnings release will be crucial in showing whether this loss was a one-off event or the start of a more sustained profitability challenge.
Gilead Sciences stock at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Nasdaq
- Market capitalization: 187.39 billion USD (as of September 8, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
